BIOMEA FUSION INC
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Stock Performance Snapshot
Analyst Rating
Analysts encourage buying BIOMEA FUSION INC's stock, predicting a significant increase in value.
Financial Health
Biomea Fusion is generating steady cash flow and book value, indicating moderate financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BMEA
Pharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: October 10, 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: September 21, 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: September 1, 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: August 28, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory steps can drive volatility; positive data may boost shares, but clinical setbacks can reverse gains.
Small-Molecule Focus
Work on novel small-molecule therapies could offer targeted advantages and partnership potential, though early science brings execution and safety risks.
Market And Size
With a market cap near $110M the stock is small and can be illiquid, which may amplify price moves and increase trading risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
